MetaVia Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTVA research report →
About the company
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
- CEO
- Hyung Heon Kim
- IPO
- 2016
- Employees
- 9
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $3.26M
- P/E
- -0.25
- P/S
- 0.00
- P/B
- 0.79
- EV/EBITDA
- 0.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -172.92%
- ROIC
- -149.42%
- Revenue
- $0 · 0.00%
- Net Income
- $-12,973,000 · 52.98%
- EPS
- $-7.35 · 81.23%
- Op Income
- $-13,708,000
- FCF YoY
- 36.47%
- 52W High
- $19.03
- 52W Low
- $0.97
- 50D MA
- $1.85
- 200D MA
- $5.08
- Beta
- 0.97
- Avg Volume
- 3.77M
Get TickerSpark's AI analysis on MTVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 26 | Tursi James Patrick | other | 17,186 |
| Jun 8, 26 | STRICKLAND D GORDON | other | 17,186 |
| Jun 8, 26 | Salsbury Michael | other | 17,186 |
| Jun 8, 26 | GROVES JASON L | other | 17,186 |
| Jun 8, 26 | KOVEN ANDREW I | other | 17,186 |
| Jun 8, 26 | Glickman Mark A | other | 17,186 |
| Jan 23, 26 | Woodworth Marshall H | other | 28,000 |
| Jan 23, 26 | Kim Hyung Heon | other | 32,000 |
| Aug 12, 25 | Woodworth Marshall H | other | 14,200 |
| Jun 30, 25 | Glickman Mark A | other | 28,147 |
Our MTVA coverage
Recent articles, reports, and earnings notes.
No research on MTVA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MTVA report →Similar companies
Peers in the same neighborhood.